Search bioRxiv⌕ Search

Biology subjects

Van de Velde, S.

Publications and source records attributed to Van de Velde, S..

2 recordsLinked to original sources

A benchmark of DNA methylation deconvolution methods for tumoral fraction estimation using DecoNFlow

In cancer patients, circulating cell-free DNA (cfDNA) is released into body fluids from both healthy and cancer cells. The proportion of tumor-derived cfDNA serves as a surrogate marker of tumor burden allowing disease monitoring. Tumoral cfDNA can be distinguished based on patient specific tumoral mutations or using more general tumor specific DNA methylation patterns, that are preserved on tumoral cfDNA. DNAm profiling of cfDNA thus enables non-invasive cancer detection and monitoring. However, accurately determining tumour fractions remains challenging due to the heterogeneous mixture of cfDNA sources in body fluids. Computational DNAm deconvolution methods address this by inferring cell-type contributions either with or without reference methylomes. While several tools exist and multiple benchmarking studies have been performed, none have specifically evaluated the sensitivity and accuracy of tumour-fraction estimation in cfDNA-focused contexts. Here, we benchmarked 10 reference-based and 2 reference-free DNAm deconvolution tools using 3,690 in silico mixtures spanning multiple tumour types, different bisulfite-based sequencing strategies and several sequencing depths. Overall, CelFiE showed the most accurate tumour-fraction estimation across the different conditions. Interestingly, reference-free methods demonstrated superior sensitivity for tumour detection, but consistent over-estimation of tumoral fraction. We further observed that sequencing depth strongly affects performance until sufficient saturation is achieved. To enable reproducible evaluation and tool selection within this benchmark, we developed DecoNFlow, a scalable Nextflow pipeline integrating 12 deconvolution tools and 3 marker selection methods, making it the most comprehensive pipeline for sequencing-based deconvolution up to date. Together, our findings provide practical guidance for tool selection in cfDNA tumour monitoring and establish DecoNFlow as a robust framework for benchmarking and applying DNAm deconvolution.

bioinformatics↗

Med14 phosphorylation shapes genomic response to GLP-1 Agonist

Under feeding conditions, release of glucagon-like peptide (GLP-1) from intestinal L cells promotes insulin secretion and pancreatic beta cell viability. Binding of GLP-1 to its cognate receptor on the beta cell surface results in induction of the cAMP signaling pathway, leading to the protein kinase A (PKA) mediated phosphorylation of CREB and induction of CREB target genes. By contrast with the acute effects of this pathway on immediate early CREB target genes, which attenuate the cAMP-CREB response, sustained exposure of beta cells to the stable GLP-1 receptor agonist Exendin-4 stimulates the expression of beta cell specific CREB target genes with delayed kinetics. In a proteomic screen for transcriptional co-regulators that mediate the long-term effects of GLP-1 analogs, we identified Med14, a backbone subunit of the Mediator complex. Exposure to Exendin-4 stimulates Med14 phosphorylation at Ser983, corresponding to a conserved PKA recognition site (RRXS) that is located within an intrinsically disordered region of Med14. Phosphorylation of Med14 by PKA is essential for maintenance of enhancers that drive induction of beta cell-specific and diabetes-linked genes. Mutation of Med14 at Ser983 to alanine decreased beta cell numbers and repressed Exendin-4 induced gene regulation in primary mouse beta cells. Our work reveals how phosphorylation of a general transcription factor in response to GLP-1 analogs triggers a broad genomic response with salutary effects on beta cell function.

genomics↗